Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.4% - Here's What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares were down 4.4% during mid-day trading on Monday . The company traded as low as $26.25 and last traded at $26.29. Approximately 101,058 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 195,626 shares. The stock had previously closed at $27.50.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Baird R W upgraded shares of Dianthus Therapeutics to a "strong-buy" rating in a research note on Friday, July 26th. Oppenheimer assumed coverage on shares of Dianthus Therapeutics in a research report on Thursday, October 3rd. They set an "outperform" rating and a $48.00 price objective on the stock. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They issued an "outperform" rating and a $58.00 price target on the stock. Wedbush dropped their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a research note on Friday, August 9th. Finally, HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $45.13.

Dianthus Therapeutics Stock Down 7.5 %

The stock has a 50-day moving average of $27.77 and a 200 day moving average of $26.12. The stock has a market cap of $746.35 million, a PE ratio of -4.39 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by ($0.01). The business had revenue of $1.86 million during the quarter, compared to analysts' expectations of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. On average, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.28 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Dianthus Therapeutics in the second quarter worth $112,000. The Manufacturers Life Insurance Company bought a new position in Dianthus Therapeutics during the second quarter valued at about $236,000. WINTON GROUP Ltd acquired a new position in shares of Dianthus Therapeutics during the second quarter worth approximately $265,000. Point72 DIFC Ltd purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at about $334,000. Finally, Virtu Financial LLC bought a new stake in Dianthus Therapeutics during the first quarter valued at about $390,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.